| Online-Ressource |
Verfasst von: | Rupp, Christian [VerfasserIn]  |
| Mummelthei, Anne [VerfasserIn]  |
| Sauer, Peter [VerfasserIn]  |
| Weiss, Karl Heinz [VerfasserIn]  |
| Schirmacher, Peter [VerfasserIn]  |
| Stiehl, Adolf [VerfasserIn]  |
| Stremmel, Wolfgang [VerfasserIn]  |
| Gotthardt, Daniel [VerfasserIn]  |
Titel: | Non-IBD immunological diseases are a risk factor for reduced survival in PSC |
Verf.angabe: | Christian Rupp, Anne Mummelthei, Peter Sauer, Karl H. Weiss, Peter Schirmacher, Adolf Stiehl, Wolfgang Stremmel and Daniel N. Gotthardt |
Jahr: | 2012 |
Umfang: | 8 S. |
Teil: | volume:33 |
| year:2013 |
| number:1 |
| pages:86-93 |
| extent:8 |
Fussnoten: | Gesehen am 15.05.2018 |
Titel Quelle: | Enthalten in: Liver international |
Ort Quelle: | Oxford : Wiley-Blackwell, 2003 |
Jahr Quelle: | 2013 |
Band/Heft Quelle: | 33(2013), 1, Seite 86-93 |
ISSN Quelle: | 1478-3231 |
Abstract: | Abstract: Background: Primary sclerosing cholangitis (PSC) is a chronic cholestatic liver disease. It is known to be associated with immunological diseases (IDs), such as inflammatory bowel disease (IBD) and autoimmune hepatitis (AIH). Aim: We evaluated the presence of IDs be sides IBD and AIH in a cohort of PSC patients, and its association with clinical outcome. Methods: This is a prospective cohort study of 195 PSC patients that were evaluated over the period 1987 – 2010 in ou r tertiary care centre. The presence of ID was determined using a retrospective chart review. IDs were subclassified into autoimmune disease (AID) and immune-mediated inflammatory disease (IMID), according to current guidelines. Results: Twenty-seven of 195 (13.8%) PSC patients had at least one additional ID other than IBD (70%) or AIH (5%). The most frequent AIDs were autoimmune thyroiditis (2.6%) and diabetes mellitus type 1 (2.1%). The most frequent IMIDs were psoriasis (3.6%) and sarcoidosis (2.1%). After more than 20 years of follow-up, concomitant IDs repre sent an independent risk factor for reduced transplantation-free survival in patients with PSC (mean: 8.9 years vs. 16.3 years, P = 0.012). Further subgroup analysis revealed a significantly reduced survival especial ly in patients with concomitant IMID (P = 0.017). Conclusion: Patients with concomitant IDs, especially IMID, are a clinically important subgroup of PSC patients. This significant phenotype warrants further genetic and immunological studies. |
DOI: | doi:10.1111/liv.12028 |
URL: | Bitte beachten Sie: Dies ist ein Bibliographieeintrag. Ein Volltextzugriff für Mitglieder der Universität besteht hier nur, falls für die entsprechende Zeitschrift/den entsprechenden Sammelband ein Abonnement besteht oder es sich um einen OpenAccess-Titel handelt.
Volltext ; Verlag: http://dx.doi.org/10.1111/liv.12028 |
| Volltext: https://onlinelibrary.wiley.com/doi/abs/10.1111/liv.12028 |
| DOI: https://doi.org/10.1111/liv.12028 |
Datenträger: | Online-Ressource |
Sprache: | eng |
Sach-SW: | autoimmune liver disease |
| biliary tract |
| cholestatic liver disease |
| Primary sclerosing cholangitis |
| retinoid metabolism |
K10plus-PPN: | 1575150492 |
Verknüpfungen: | → Zeitschrift |
Non-IBD immunological diseases are a risk factor for reduced survival in PSC / Rupp, Christian [VerfasserIn]; 2012 (Online-Ressource)